Drug
Hypericin clinical trials
Also written SGX301.
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 3
Soligenix (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Ellen Kim, MD (1)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Studies
Open first, then newest update. How each study uses hypericin is read from its arms, and is right about nine times in ten.
Testing it · 7
- Topical SGX302 for Mild-to-Moderate PsoriasisCompletedPhase 2SoligenixNCT05442190Written as Hypericin
- Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLTerminatedPhase 3SoligenixNCT06470451Written as Hypericin
- Treatment of Mycosis Fungoides With Hypericin Ointment and Visible LightCompletedPhase 2Ellen Kim, MDNCT05872854Written as Hypericin
- HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCLCompletedPhase 2SoligenixNCT06149247Written as Hypericin
- PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaCompletedPhase 2SoligenixNCT05380635Written as Hypericin
- A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected SubjectsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000792Written as Hypericin
- A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 LymphocytesCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000645Written as Hypericin
Codes
What other systems call hypericin · ClinicalTrials.gg INT002310
- MeSH (NLM) C004965hypericinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7V2F1075HDHYPERICINConfirmed FDA, NLM, Wikidata
- RxNorm 1546455Confirmed FDA, Wikidata
- Wikidata Q425409hypericinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C37456HypericinOne source FDA
- DrugBank DB13014One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C004965 | hypericin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7V2F1075HD | HYPERICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1546455 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425409 | hypericin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C37456 | Hypericin | One source FDA |
| DrugBank | DB13014 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.